131 related articles for article (PubMed ID: 25012458)
1. Preclinical evaluation of 3-18F-fluoro-2,2-dimethylpropionic acid as an imaging agent for tumor detection.
Witney TH; Pisaneschi F; Alam IS; Trousil S; Kaliszczak M; Twyman F; Brickute D; Nguyen QD; Schug Z; Gottlieb E; Aboagye EO
J Nucl Med; 2014 Sep; 55(9):1506-12. PubMed ID: 25012458
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Effective Detection and Monitoring of Glioma Using [
Vassileva V; Braga M; Barnes C; Przystal J; Ashek A; Allott L; Brickute D; Abrahams J; Suwan K; Carcaboso AM; Hajitou A; Aboagye EO
Biomedicines; 2021 Jul; 9(7):. PubMed ID: 34356874
[TBL] [Abstract][Full Text] [Related]
4. Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer.
Wuest M; Trayner BJ; Grant TN; Jans HS; Mercer JR; Murray D; West FG; McEwan AJ; Wuest F; Cheeseman CI
Nucl Med Biol; 2011 May; 38(4):461-75. PubMed ID: 21531283
[TBL] [Abstract][Full Text] [Related]
5. Clinical translation of
Dubash SR; Keat N; Kozlowski K; Barnes C; Allott L; Brickute D; Hill S; Huiban M; Barwick TD; Kenny L; Aboagye EO
Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2549-2561. PubMed ID: 32123971
[TBL] [Abstract][Full Text] [Related]
6. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
7. Molecular Imaging of GLUT1 and GLUT5 in Breast Cancer: A Multitracer Positron Emission Tomography Imaging Study in Mice.
Wuest M; Hamann I; Bouvet V; Glubrecht D; Marshall A; Trayner B; Soueidan OM; Krys D; Wagner M; Cheeseman C; West F; Wuest F
Mol Pharmacol; 2018 Feb; 93(2):79-89. PubMed ID: 29142019
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model.
Wang HE; Wu SY; Chang CW; Liu RS; Hwang LC; Lee TW; Chen JC; Hwang JJ
Nucl Med Biol; 2005 May; 32(4):367-75. PubMed ID: 15878506
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Bioevaluation of Novel [
Yang X; Wang F; Zhu H; Yang Z; Chu T
Mol Pharm; 2019 May; 16(5):2118-2128. PubMed ID: 30964298
[TBL] [Abstract][Full Text] [Related]
10. Functional imaging of oxidative stress with a novel PET imaging agent, 18F-5-fluoro-L-aminosuberic acid.
Webster JM; Morton CA; Johnson BF; Yang H; Rishel MJ; Lee BD; Miao Q; Pabba C; Yapp DT; Schaffer P
J Nucl Med; 2014 Apr; 55(4):657-64. PubMed ID: 24578242
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Tryptophan Uptake and Kinetics Using 1-(2-18F-Fluoroethyl)-l-Tryptophan and α-11C-Methyl-l-Tryptophan PET Imaging in Mice Implanted with Patient-Derived Brain Tumor Xenografts.
Michelhaugh SK; Muzik O; Guastella AR; Klinger NV; Polin LA; Cai H; Xin Y; Mangner TJ; Zhang S; Juhász C; Mittal S
J Nucl Med; 2017 Feb; 58(2):208-213. PubMed ID: 27765857
[TBL] [Abstract][Full Text] [Related]
12. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
Bouvet V; Wuest M; Bailey JJ; Bergman C; Janzen N; Valliant JF; Wuest F
Mol Imaging Biol; 2017 Dec; 19(6):923-932. PubMed ID: 28639122
[TBL] [Abstract][Full Text] [Related]
13. Positron Emission Tomography (PET) and Pharmacokinetics: Classical Blood Sampling Versus Image-Derived Analysis of [18F]FAZA and [18F]FDG in a Murine Tumor Bearing Model.
Jans HS; Yang XH; Brocks DR; Kumar P; Wuest M; Wiebe LI
J Pharm Pharm Sci; 2018; 21(1s):32s-47s. PubMed ID: 29702045
[TBL] [Abstract][Full Text] [Related]
14. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG
Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970
[TBL] [Abstract][Full Text] [Related]
15. Impact of structural alterations on the radiopharmacological profile of
Tietz O; Marshall A; Bergman C; Wuest M; Wuest F
Nucl Med Biol; 2018; 62-63():9-17. PubMed ID: 29800798
[TBL] [Abstract][Full Text] [Related]
16. Validation of R-2-[
Zhang Z; Liu S; Ma H; Nie D; Wen F; Zhao J; Sun A; Yuan G; Su S; Xiang X; Hu P; Tang G
Mol Imaging Biol; 2019 Dec; 21(6):1127-1137. PubMed ID: 30847820
[TBL] [Abstract][Full Text] [Related]
17. [
Hovhannisyan N; Fillesoye F; Guillouet S; Ibazizene M; Toutain J; Gourand F; Valable S; Plancoulaine B; Barré L
Theranostics; 2018; 8(16):4563-4573. PubMed ID: 30214639
[TBL] [Abstract][Full Text] [Related]
18. High in-vivo stability in preclinical and first-in-human experiments with [
Qin X; Guo X; Liu T; Li L; Zhou N; Ma X; Meng X; Liu J; Zhu H; Jia B; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):302-313. PubMed ID: 36129493
[TBL] [Abstract][Full Text] [Related]
19. 18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas.
Sai KK; Huang C; Yuan L; Zhou D; Piwnica-Worms D; Garbow JR; Engelbach JA; Mach RH; Rich KM; McConathy J
J Nucl Med; 2013 Jul; 54(7):1120-6. PubMed ID: 23650628
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo characterization of 2-deoxy-2-18F-fluoro-D-mannose as a tumor-imaging agent for PET.
Furumoto S; Shinbo R; Iwata R; Ishikawa Y; Yanai K; Yoshioka T; Fukuda H
J Nucl Med; 2013 Aug; 54(8):1354-61. PubMed ID: 23843565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
